[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331231-105":59,"doc-detail-331231-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sacituzumab-govitecan-in-triple-negative-breast-cancer-from-bench-to-bedside-and-back","Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back","","Triple-negative breast cancer (TNBC) poses major therapeutic challenges due to its heterogeneous, aggressive biology and limited target-specific options. Trop-2, a transmembrane glycoprotein, has been identified as a promising target, enabling sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate. SG has entered treatment algorithms for advanced and metastatic TNBC with manageable toxicity. Open issues remain regarding efficacy, safety, and Trop-2’s biological and predictive roles, including variability across primary versus metastatic sites and interactions with other biomarkers, requiring further research and clinical evaluation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sacituzumab-govitecan-in-triple-negative-breast-cancer-from-bench-to-bedside-and-back/331231/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sacituzumab-govitecan-in-triple-negative-breast-cancer-from-bench-to-bedside-and-back/331231.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is TNBC considered a major therapeutic challenge?","Question",{"text":112,"@type":113},"TNBC is heterogeneous and aggressive, with limited target-specific treatment options and outcomes driven by early relapse and poor survival after metastatic onset.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is sacituzumab govitecan (SG) and what does it target?",{"text":117,"@type":113},"SG is an antibody-drug conjugate that targets Trop-2, a glycoprotein overexpressed in various cancers, and it has been used in advanced or metastatic TNBC treatment algorithms.",{"name":119,"@type":110,"acceptedAnswer":120},"What uncertainties remain about SG and Trop-2 in TNBC?",{"text":121,"@type":113},"Questions remain about SG’s efficacy and safety profile and about whether Trop-2 can function as a predictive biomarker, including heterogeneity of Trop-2 levels across TNBC cases and site-specific differences.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331231,1790141423,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Mini Review  \nPUBLISHED 15 August 2024  \nDOI 10.3389/fimmu.2024.1447280  \nOPEN ACCESS  \nEDITED BY  \nLisheng Wang,  \nUniversity of Ottawa, Canada  \nREVIEWED BY  \nSaverio Alberti,  \nUniversity of Messina, Italy  \n*CORRESPONDENCE Debora Carpanese  \n [debora.carpanese@iov.veneto.it](debora.carpanese@iov.veneto.it)  \n†These authors have contributed equally to this work and share first authorship  \n‡These authors have contributed equally to this work and share last authorship  \nRECEIVED 11 June 2024  \nACCEPTED 26 July 2024  \nPUBLISHED 15 August 2024  \nCITATION  \nRossi V, Turati A, Rosato A and Carpanese D (2024) Sacituzumab govitecan in triplenegative breast cancer: from bench to bedside, and back.  \nFront. Immunol. 15:1447280 .  \ndoi: 10.3389/fimmu.2024.1447280  \nCOPYRIGHT  \n© 2024 Rossi, Turati, Rosato and Carpanese. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nSacituzumab govitecan in triplenegative breast cancer: from bench to bedside, and back  \nValentina Rossi 1†, Alessandra Turati 1†, Antonio Rosato 1,2‡ and Debora Carpanese 1*‡  \n1 Immunology and Molecular Oncology Unit, Veneto Institute of Oncology (IOV)-IRCCS, Padova, Italy, 2 Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy  \nTriple-negative breast cancer (TNBC) represents a major therapeutic challenge due to its heterogeneous and aggressive phenotype, and limited target-specific treatment options. The trophoblast cell surface antigen (Trop-2), atransmembrane glycoprotein overexpressed in various cancers, has emerged as a promising target for TNBC. Sacituzumab govitecan (SG), an antibody-drug conjugate (ADC) that targets Trop-2, has recently entered treatment algorithms for advanced and metastatic TNBC, independently from Trop-2 expression status, with manageable toxicity. Despite the impressive results, questions remain unsolved regarding its efficacy, safety profile, and Trop-2 biological role in cancer . Currently, Trop-2 cannot be designated as a predictive biomarker in SG treatment, albeit its expression correlates with disease outcome, yet its levels are not uniform across all TNBCs. Additionally, data regarding Trop-2 expression variations in primary and metastatic sites, and its interplay with other biomarkers are still ambiguous but mandatory in light of future applications of SG in other indications and settings. This poses the questions of a careful evaluation of the efficacy and toxicity profile of SG in such early stages of disease, and in personalized and combinatorial strategies. Research and clinical data are mandatory to address SG drawbacks and minimize its benefits, to realize its full potential as therapeutic agent in different epithelial tumors.  \nKEYWORDS  \ntriple negative breast cancer (TNBC), sacituzumab govitecan (IMMU-132), antibodydrug conjugate (ADC), Trop-2, immunotherapy, target therapeutics, metastatic TNBC  \nIntroduction  \nBreast cancer (BC) is one of the leading causes of female mortality (1), where triplenegative breast cancer (TNBC) subtype represents 15%-25% of all cases. This malignancy is characterized by high invasiveness, metastatic potential to distant sites, such as bone, lung, liver, and brain (2), leading to increased mortality rates, proneness to relapse (3), and short  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nsurvival after the onset of metastatic disease (4) . The aggressive tumor behavior and limited treatment options highlight the urgency to identify novel prognostic biomarkers and cancer-specific therapeutic targets to improve patient outcomes. Trophoblast cell s","cbCaigcm7ArUrLaT","https://ap.wps.com/l/cbCaigcm7ArUrLaT","pdf",2398686,"English","# Introduction\n## Triple-negative breast cancer: treatment options and new promising possibilities","[{\"question\":\"Why is TNBC considered a major therapeutic challenge?\",\"answer\":\"TNBC is heterogeneous and aggressive, with limited target-specific treatment options and outcomes driven by early relapse and poor survival after metastatic onset.\"},{\"question\":\"What is sacituzumab govitecan (SG) and what does it target?\",\"answer\":\"SG is an antibody-drug conjugate that targets Trop-2, a glycoprotein overexpressed in various cancers, and it has been used in advanced or metastatic TNBC treatment algorithms.\"},{\"question\":\"What uncertainties remain about SG and Trop-2 in TNBC?\",\"answer\":\"Questions remain about SG’s efficacy and safety profile and about whether Trop-2 can function as a predictive biomarker, including heterogeneity of Trop-2 levels across TNBC cases and site-specific differences.\"}]","Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back | PDF",1789992333,25]